News
HRTX
1.635
+6.86%
0.105
Weekly Report: what happened at HRTX last week (1223-1227)?
Weekly Report · 12/30/2024 11:03
Heron Therapeutics Relocates Headquarters to North Carolina
TipRanks · 12/23/2024 21:31
Heron Therapeutics relocates corporate headquarters to Cary, North Carolina
TipRanks · 12/23/2024 21:10
Weekly Report: what happened at HRTX last week (1216-1220)?
Weekly Report · 12/23/2024 11:09
Weekly Report: what happened at HRTX last week (1209-1213)?
Weekly Report · 12/16/2024 11:10
Weekly Report: what happened at HRTX last week (1202-1206)?
Weekly Report · 12/09/2024 11:08
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/06/2024 16:20
Largest borrow rate increases among liquid names
TipRanks · 12/06/2024 13:50
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
TipRanks · 12/05/2024 16:10
Heron Therapeutics Secures Revenue Stream with Court Ruling, Analyst Recommends Buy
TipRanks · 12/05/2024 16:07
3 Penny Stocks to Watch Now, 12/5/24
TipRanks · 12/05/2024 11:28
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/04/2024 21:06
Relief For Heron Therapeutics After The Court Win On Cinvanti
Seeking Alpha · 12/04/2024 20:01
BUZZ-U.S. STOCKS ON THE MOVE-Nano Nuclear, JetBlue, Cross Country
Reuters · 12/04/2024 16:05
Heron Therapeutics patent victory removes ‘major overhang,’ says Northland
TipRanks · 12/04/2024 13:50
Heron Therapeutics Price Target Maintained With a $4.00/Share by Needham
Dow Jones · 12/04/2024 11:56
Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target
Benzinga · 12/04/2024 11:45
BUZZ-Heron Therapeutics jumps on favorable court ruling over Cinvanti patents
Reuters · 12/04/2024 11:43
HERON THERAPEUTICS SHARES UP 81.4% PREMARKET AFTER U.S. DISTRICT COURT RULED IN CO'S FAVOR IN PATENT LITIGATION AGAINST FRESENIUS KABI USA
Reuters · 12/04/2024 10:47
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/04/2024 10:11
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.